Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Relapsed glioblastoma.
- Who it may be relevant to
- Registry conditions: Relapsed Cancer, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.
Overview
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
Detailed description
Glioblastomas are the most frequent and aggressive malignant Central Nervous System (CNS) tumors in adults, with a median survival of only 14 months.
Current treatment is based on surgery followed by radiochemotherapy (STUPP protocol), unchanged since 2005. Clinical trials evaluating immune checkpoint inhibitors and targeted therapies have largely failed to demonstrate efficacy in these tumors. In order to better understand the oncogenesis of glioblastoma and identify potential new therapeutic targets, the study of the characteristics of relapsed tumors compared with the initial tumor seems relevant.
The aim of this retrospective study is to investigate the transcriptomic, proteomic and metabolic characteristics of relapsed glioblastomas reoperated at the University Hospital of Bordeaux, France, between 2005 and 2023, for which tumor material is available. These analyses will be correlated with relapse-free and overall survival of the patients.
Interventions
- Biological Relapsed glioblastoma
Paired tumor samples diagnosis/relapse
Primary outcome measures
- Evaluation of metabolic changes involved in glioblastoma relapse [Time frame: Up to 2 years after the start of the study]
Secondary outcome measures (2)
- Progression-free survival [Time frame: From date of the second surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years]
- Overall survival [Time frame: From date of the second surgery until the date of death from any cause, assessed up to 5 years]
Eligibility criteria
Inclusion criteria
- age > 18 years
- surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
Exclusion criteria
- systemic therapy received for non-glioblastoma tumor
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale — Bordeaux
Identifiers
NCT: NCT06430424 · CHUBX 2023/79